micro-community-banner
Profile Image
  • Saved
Safety of PCSK9 inhibitors

Safety of PCSK9 inhibitors

Source : https://www.sciencedirect.com/science/article/pii/S0753332222013464?via=ihub

PCSK9 inhibitors do not affect the increase in new cases of diabetes. * Treatment with PCSK9 inhibitors has a lower risk of muscle side effects. * PCSK9 inhibitors do not...

/>


Relevance: The purpose of this review is to summarize information on the safety profile of PCSK9 inhibitors, which may help in making therapeutic decision.

Profile Image
  • Saved
Real-World Data on Comparison of Lipid-Lowering Effects between Alirocumab and Evolocumab in Patients with Hypercholesterolemia - PubMed

Real-World Data on Comparison of Lipid-Lowering Effects between Alirocumab and Evolocumab in Patients with Hypercholesterolemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36440240/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....



Conclusions: The LDL-C lowering effects of alirocumab are similar to those of evolocumab in clinical practice.

Profile Image
  • 3yr
    Key Points • Source: Acta Cardiologica Sinica • Conclusions: “The LDL-C lowering effects of alirocumab are similar to those of evolocumab in clinical practice.” • Taiwanese researchers compared characteristics, prescribed medications, plasma LDL-C levels, and percentages Show More
  • Saved
Statin intolerance management: a systematic review - Endocrine

Statin intolerance management: a systematic review - Endocrine

Source : https://link.springer.com/article/10.1007/s12020-022-03263-w

Background Statin intolerance is a key barrier to the effective prevention of atherosclerotic cardiovascular disease (ASCVD). Experts do not agree on what it is and how to respond to this...



Conclusion: We found substantial variability in the definition and management of statin intolerance among experts. Few focused on ASCVD risk reduction and none promoted the participation of patients in shared decision making about how to address the threat of ASCVD with or without statins.

Profile Image
  • Saved
New Trends and Therapies for Familial Hypercholesterolemia - PubMed

New Trends and Therapies for Familial Hypercholesterolemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36431115/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....



Conclusions/Relevance: Newer therapies such as inhibitors of microsomal transfer protein and angiopoietin-like protein 3 have opened the possibility of LDL-cholesterol normalization in homozygous FH and may provide an alternative to lipoprotein apheresis for these patients. Gene-based therapies may provide more definite solutions for lowering...

Profile Image
  • Saved
Genome Editing in Dyslipidemia and Atherosclerosis

Genome Editing in Dyslipidemia and Atherosclerosis

Source : https://link.springer.com/chapter/10.1007/978-981-19-5642-3_10

Hardcover Book USD 199.99 Price excludes VAT (USA) We acknowledge the Servier Medical Art for providing basic graph elements for our figures, PubMed for publication statistics, and NHGRI-EBI GWAS Catalog...



Relevance: We give an outlook on the potential gene targets prioritized by large-scale genetic studies of cardiovascular diseases and genome editing in precision medicine of dyslipidemia and atherosclerosis.

Profile Image